Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity

Molnupiravir is a β-d-N4-hydroxycytidine-5′-isopropyl ester (NHC) compound that exerts antiviral activity against various RNA viruses such as influenza, SARS, and Ebola viruses. Thus, the repurposing of Molnupiravir has gained significant attention for combatting infection with SARS-CoV-2, the etiol...

Detaylı Bibliyografya
Asıl Yazarlar:	Ashley Jia Wen Yip, Zheng Yao Low, Vincent T. K. Chow, Sunil K. Lal
Materyal Türü:	Makale
Dil:	English
Baskı/Yayın Bilgisi:	MDPI AG 2022-06-01
Seri Bilgileri:	Viruses
Konular:	COVID-19 SARS-CoV-2 repurposing repositioning antiviral Molnupiravir
Online Erişim:	https://www.mdpi.com/1999-4915/14/6/1345

Benzer Materyaller

Antiviral Efficacy of Molnupiravir for COVID-19 Treatment
Yazar:: Yuan Bai, ve diğerleri
Baskı/Yayın Bilgisi: (2022-04-01)

Molnupiravir and Its Antiviral Activity Against COVID-19
Yazar:: Lili Tian, ve diğerleri
Baskı/Yayın Bilgisi: (2022-04-01)

Why Molnupiravir Fails in Hospitalized Patients
Yazar:: Ashley N. Brown, ve diğerleri
Baskı/Yayın Bilgisi: (2022-12-01)

Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial
Yazar:: Rongrong Zou, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval
Yazar:: Ashour NA, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
Yazar:: Samuel Theodorus Sutanto, ve diğerleri
Baskı/Yayın Bilgisi: (2022-12-01)

Real-Life Experience of Molnupiravir in Hospitalized Patients Who Developed SARS-CoV2-Infection: Preliminary Results from CORACLE Registry
Yazar:: Tommaso Lupia, ve diğerleri
Baskı/Yayın Bilgisi: (2022-11-01)

Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel
Yazar:: Clara Weil, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

Multidrug Combinations against SARS-CoV-2 Using GS-441524 or Ivermectin with Molnupiravir and/or Nirmatrelvir in Reconstituted Human Nasal Airway Epithelia
Yazar:: Denise Siegrist, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

Interaction and antiviral treatment of coinfection between SARS-CoV-2 and influenza in vitro
Yazar:: Danlei Liu, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19
Yazar:: Giuseppe Bruno, ve diğerleri
Baskı/Yayın Bilgisi: (2022-11-01)

Real-World Use of Molnupiravir in the Treatment of Outpatients with SARS-CoV-2 Infection—A Patient Profile Based on the Experience of a Tertiary Infectious Disease Center
Yazar:: Anca Streinu-Cercel, ve diğerleri
Baskı/Yayın Bilgisi: (2022-08-01)

The new oral antiviral agents for COVID-19
Yazar:: S.L. Seneviratne, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild–Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or Remdesivir
Yazar:: Francesca Bai, ve diğerleri
Baskı/Yayın Bilgisi: (2024-06-01)

Molnupiravir: From Hope to Epic Fail?
Yazar:: Daniele Focosi
Baskı/Yayın Bilgisi: (2022-11-01)

Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review
Yazar:: Jennifer Santos, ve diğerleri
Baskı/Yayın Bilgisi: (2020-06-01)

Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity against Enterovirus Infections In Vitro and In Vivo
Yazar:: Yuexiang Li, ve diğerleri
Baskı/Yayın Bilgisi: (2022-05-01)

Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation studyResearch in context
Yazar:: Eric Yuk Fai Wan, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Effectiveness of molnupiravir for treating COVID-19 in patients with psychiatric disorders
Yazar:: Ting-Hui Liu, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis
Yazar:: Huzaifa Ahmad Cheema, ve diğerleri
Baskı/Yayın Bilgisi: (2024-06-01)

Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
Yazar:: Vassiliki Spiliopoulou, ve diğerleri
Baskı/Yayın Bilgisi: (2023-03-01)

Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID‐19: A systematic review and meta‐analysis
Yazar:: Bahman Amani, ve diğerleri
Baskı/Yayın Bilgisi: (2024-04-01)

Prevention is better than healing. Clinical and economic implications of oral antiviral agents in COVID-19: a prospective study
Yazar:: Filomena Pietrantonio, ve diğerleri
Baskı/Yayın Bilgisi: (2024-06-01)

Cost of Goods Analysis Facilitates an Integrated Approach to Identifying Alternative Synthesis Methodologies for Lower Cost Manufacturing of the COVID-19 Antiviral Molnupiravir [version 1; peer review: 2 approved]
Yazar:: Christopher Peterson, ve diğerleri
Baskı/Yayın Bilgisi: (2022-02-01)

SARS‐CoV‐2 PLpro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment
Yazar:: B.Sc. Sara Protić, ve diğerleri
Baskı/Yayın Bilgisi: (2024-11-01)

Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy
Yazar:: Tonino Alonzi, ve diğerleri
Baskı/Yayın Bilgisi: (2021-12-01)

Molnupiravir in Combination with Remdesivir for Severe COVID-19 Patients Admitted to Hospital: a Case Series
Yazar:: Seyed Mohammad Reza Hashemian, ve diğerleri
Baskı/Yayın Bilgisi: (2022-04-01)

Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19
Yazar:: Mohd. Imran, ve diğerleri
Baskı/Yayın Bilgisi: (2021-09-01)

Molnupiravir; an effective drug in treating COVID-19?
Yazar:: Alireza Pouramini, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

Molnupiravir When Used Alone Seems to Be Safe and Effective as Outpatient COVID-19 Therapy for Hemodialyzed Patients and Kidney Transplant Recipients
Yazar:: Paweł Poznański, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies
Yazar:: Reham F. Barghash, ve diğerleri
Baskı/Yayın Bilgisi: (2024-11-01)

The study of antiviral drugs targeting SARS-CoV-2 nucleocapsid and spike proteins through large-scale compound repurposing
Yazar:: Xuqiao Hu, ve diğerleri
Baskı/Yayın Bilgisi: (2021-03-01)

Comparison of the acceptability and safety of molnupiravir in COVID-19 patients aged over and under 80 years
Yazar:: Kohei Fujita, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro
Yazar:: Anna Gidari, ve diğerleri
Baskı/Yayın Bilgisi: (2022-07-01)

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
Yazar:: Ivan Gentile, ve diğerleri
Baskı/Yayın Bilgisi: (2022-10-01)

Valinomycin as a potential antiviral agent against coronaviruses: A review
Yazar:: Dong Zhang, ve diğerleri
Baskı/Yayın Bilgisi: (2020-10-01)

Management of Kidney Transplant Outpatients With COVID-19: A Single Center Experience
Yazar:: Michaela Matysková Kubišová, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

The effect of oral antiviral therapy for COVID-19 in managing non-hospitalized patients with lung cancer
Yazar:: Wan-Hsuan Hsu, ve diğerleri
Baskı/Yayın Bilgisi: (2024-08-01)

MOLNUPIRAVIR (MOL) COMPARADO A NIRMATRELVIR/RITONAVIR (NIRI) PARA COVID-19 EM PACIENTES DE ALTO RISCO COM MALIGNIDADE HEMATOLÓGICA NA EUROPA: UMA ANÁLISE PAREADA DO REGISTRO EPICOVIDEHA
Yazar:: Jon Salmanton-García, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

COVID-19 at a Glance: An Up-to-Date Overview on Variants, Drug Design and Therapies
Yazar:: Domenico Iacopetta, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)